Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 15/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 15/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 9/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648677 | 0.81 | MAPK14 (0.57) | KCNJ6KCNJ3KCNJ5MAPK14MAPK13 | |
| SCHEMBL31391212 | 0.75 | KCNJ6 (0.61) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2246430 | 0.72 | KCNJ6 (0.47) | KCNJ6KCNJ3KCNJ5MAPK14 | |
| SCHEMBL31391193 | 0.70 | KCNJ6 (0.64) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL31265667 | 0.69 | KCNJ6 (0.50) | KCNJ6KCNJ3KCNJ5MAPK14MAPK13 | |
| SCHEMBL13234475 | 0.68 | KCNJ6 (0.92) | KCNJ6KCNJ3KCNJ5CYP3A4GAA | |
| SCHEMBL2243890 | 0.68 | MAPK14 (0.51) | KCNJ6KCNJ3KCNJ5MAPK14MAPK13 | |
| SCHEMBL2242359 | 0.68 | MAPK14 (0.51) | KCNJ6KCNJ3KCNJ5MAPK14MAPK13 | |
| SCHEMBL25246469 | 0.68 | BRAF (0.55) | KCNJ6KCNJ3KCNJ5MAPK14 | |
| SCHEMBL30486131 | 0.68 | BRAF (0.55) | KCNJ6KCNJ3KCNJ5MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007059202-A2 | PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE AG (DE) | 2007-05-24 | — | — | WO | disclosed |